Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac sympathetic nerve imaging agents, 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG).

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Michigan

Criteria

Inclusion Criteria:

• Non-obese (BMI < 30)

• Normal blood pressure

• Normal blood lipid profile

• No history of prior cardiovascular disease

• Not susceptible to claustrophobia

• Ability to lay flat for 90 min

Exclusion Criteria:

• Obesity (BMI > 30)

• Risk factors for heart disease (age > 55y, hypertension, smoking, high blood pressure, high cholesterol levels, diabetes, etc.)

• History of heart disease (heart attack, atrial fibrillation, ventricular tachycardia, exertional angina)

• Currently using certain medications that may interact with cardiac nerves (antidepressants, cold medications, nasal decongestants, monoamine oxidase inhibitors, etc.)

• Claustrophobia

• Inability to lie flat for 90 min

• Pregnant or breast feeding